## Figures





Fig. 1





Fig. 2



(a)
Z.average [nm]
c P188 [% w/v]
(b)
encapsulation efficiency [%]
c P188 [% w/v]
(c)
rel. mRNA integrity [%]
c P188 [% w/v]
untreated
after nebulization

Fig. 3



(a)
Z.average [nm]
Nebulization time [min]
(b)
PdI []
Nebulization time [min]
(c)
Encapsulation efficiency [%]
Nebulization time [min]
(d)
rel. mRNA integrity [%]
Nebulization time [min]

Fig. 4



untreated
after nebulization
200
150
100
50
0
eGFP [ng/g]
Poloxamer
Tween-80

Fig. 5



w/o excipient
5% Poloxamer
100
10
1
eGFP [ng/g]
0
5
10
Dose [µg]

Fig. 6



200
150
100
50
0
Z.average [nm]
0.6
0.4
0.2
0.0
PdI [ ]
complexation
downstream processing
size w/o
PdI w/o
size P188
PdI P188

Fig. 7



400
300
200
100
0
Z.average [nm]
1.0
0.8
0.6
0.4
0.2
0.0
PdI [ ]
before
after
size w/o
PdI w/o
size with Poloxamer
PdI with Poloxamer

Fig. 8



400
300
200
100
0
Z.average [nm]
1.0
0.8
0.6
0.4
0.2
0.0
PdI [ ]
before
after
size w/o
PdI w/o
size P188
PdI P188

Fig. 9

5